Part 5 – Healthy America: Medical Tourism, Peptides, and the Future of Medicine
Kelly Kleinman: Part 5: Dino Guglielmelli of Planet One Company and Jeff Cantor of Healthy America discuss opportunities in medical tourism, cutting-edge treatment modalities, the Healthy America Initiative, and other opportunities on the horizon and in the here and now.
Jeff K: We're sitting in the middle of a huge population base in Akron. It's almost equidistant between Chicago and New York, which positions the area to become a medical tourism destination.
This is just one example of what's been developing organically. Without us having to make much effort, word is getting out, and the calls are starting to pour in. People recognize that here's a train they can finally jump on that's actually going somewhere.
Then they look around to see who's on the masthead and say, "Oh my gosh, this is a who's who of people I've idolized or always wanted an opportunity to meet."
Now, all of these people have the opportunity to come together and meet one another at a shared event. That's what's been so exciting about this. You're going to love it.
Dino Guglielmelli: I want to talk about peptides for a minute. We've touched on this before, but it's an important subject.
Peptides were never originally intended to be packaged in vials and distributed for use in people's homes. Injectable formulations were intended for clinical settings, such as IV rooms and hospitals, where qualified registered nurses could administer them. They weren't originally intended for use in gyms or private homes.
Somehow, that market opened up, and I think the industry was somewhat slow to recognize what was happening. Now, the issue has come to a head.
For the past four and a half years, I've been working with oral peptides using what I believe is a responsible microdosing approach, and I'm seeing tremendous results.
The original narrative surrounding peptides, particularly injectable formulations, was that they couldn't survive the digestive process and reach the bloodstream unless they were administered directly into it. However, that isn't necessarily true of every formulation. Certain delayed-release delivery technologies are designed to protect compounds through the digestive tract and release them in the small intestine. The effectiveness and absorption depend on the specific peptide and formulation.
We're seeing encouraging results, and I want to talk more about how these approaches work. But, again, the treatments need to be properly targeted and administered responsibly.
There was recently a news story about someone who supposedly died from using peptides. But the individual actually died in 2025 from a heart attack after an overdose. That's almost two years ago, yet the coverage makes it sound as though it happened last week.
Jeff K: That's what I thought.
Dino Guglielmelli: Exactly. You have to read the fine print. The report says March 2025. It involved an actor in Australia.
This is what happens, and the lobbying influence surrounding these issues is incredibly strong. It's frustrating.
I'm getting tremendous feedback from doctors who are interested in peptides, but many are hesitant because they're unsure where the regulatory environment is headed.
I have FDA consultants I work with regularly because I have to stay ahead of these developments. Ultimately, the FDA is the regulatory authority I must answer to, whether I'm operating under a particular regulatory pathway or through my drug manufacturing license. I have to follow the applicable rules and guidance.
Where regulations are clearly defined, we have to comply. Where there are areas that haven't been clearly addressed, businesses need to understand what is and isn't permissible while the regulatory framework continues to evolve.
I'm a believer in free enterprise and the ability to innovate responsibly, regardless of what other political or ideological interests might prefer.
We need to become more vocal about the potential of these treatments and the importance of using them responsibly.
I believe the future of medicine will increasingly involve peptides, stem cells, exosomes, and another emerging area: ribosomes.
Ribosomes are particularly interesting. There's a patented technology that I'm preparing to work with alongside a very high-level physician. We're looking at bringing this technology forward, and I believe it could become another important development in medicine.
These are the kinds of innovations that have the potential to change healthcare, and we want to be at the forefront of advancing them responsibly.
Jeff K: There's going to be a major focus on peptides at this particular event, so you're definitely going to want to be part of that panel.
Dino Guglielmelli: Absolutely. I want to talk about Cerebrolysin, MP12, Montsea, BPC-157, TB-4, Frank, KPV, and some of the other compounds we're working with.
Jeff K: Hold on one second, Dino.
Kelly Kleinman: Can you get Dino on the panel?
Jeff K: Oh, absolutely. Definitely.
The only challenge we've had with this particular event has been the timing. In retrospect, it was a little unfortunate because it falls around the midterm elections. We had originally planned to hold it a week earlier, but we pushed it back, and now some of our people and other participants have scheduling conflicts with competing events.
As a result, we'll have a somewhat smaller crowd, but that may actually work to our advantage.
We're holding the event at Hop Springs, an 85-acre beverage manufacturing facility. They manufacture infused products for companies like Pepsi, Coca-Cola, and others.
You're going to have a field day meeting the principals behind this operation and learning about what they're doing. There's tremendous potential for connections beyond the event itself.
Dino Guglielmelli: Oh, you said November 11th, right? I'm actually going to be in Asia. I'll be in Korea and Shanghai.
Jeff K: Well, that's fine. These things happen. You'll be here for the January Hula Bowl, though.
Regardless, I'll start getting you involved now, even if you can't make this particular event. There's too much happening for you not to be part of the conversation today.
Dino Guglielmelli: Absolutely. I'm at the forefront of this. I've been working with oral peptides longer than anyone I personally know in that space.
I understand how to work with them, how to process them, and how to approach their application. We're already doing this with some of the biggest names in the country.
This is where medicine is heading. It's the future.
Our goal is to help people improve their health proactively through preventative approaches while also supporting faster recovery and restoration.
Even when someone is dealing with a regenerative need following some type of trauma or injury, we're exploring ways to help accelerate the body's recovery process.
That's what this is all about: improving health, supporting recovery, and advancing the future of medicine.
Kelly Kleinman: All right, guys. Thank you. Thank you both so much. Jeff, I really appreciate it, and Dino, thank you as well.
We'll talk to everyone soon!

